Obsessive-Compulsive Disorder Drugs Market size to grow by USD 266.78 million from 2021 to 2026, Driven by the rising prevalence of OCD - Technavio

NEW YORK, April 11, 2023 /PRNewswire/ -- The obsessive-compulsive disorder drugs market size is forecast to increase by USD 266.78 million from 2021 to 2026, at a CAGR of 5.55%, according to the recent market study by Technavio. The growth of the market will be driven by the rising prevalence of OCD, the launch of new molecules, and awareness programs for OCD. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View Sample Report 

Technavio categorizes the global obsessive-compulsive disorder drugs market Vendor Analysis:

The global OCD market is fragmented due to the presence of numerous generic as well as branded drugs. Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Apotex Inc., Biohaven Pharmaceutical Holding Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H Lundbeck AS, Jazz Pharmaceuticals Plc, Lannett Co. Inc., Lupin Ltd., Mallinckrodt Plc, Novartis AG, Omeros Corp., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.

Vendor Offerings -

• AbbVie Inc. - The company offers VRAYLAR which is a prescription medicine used in adults for the treatment of obsessive-compulsive disorder.
• Apotex Inc. - The company offers Paroxetine tablets that are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder as defined in the DSM-IV.
• Biohaven Pharmaceutical Holding Co. Ltd. - The company offers Troriluzole that modulates glutamate in an effort to reduce the severity of anxiety, worry, and functional impairment of people with anxiety.

Charts & data tables about market and segment sizes during the forecast period (2022-
2026) have been covered in this report. Download The Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Get a holistic overview of the endoscopic closure devices market by industry experts to
evaluate and develop growth strategies. Download the Sample

Obsessive-Compulsive Disorder Drugs Market - Market Segmentation:

This report extensively covers obsessive-compulsive disorder drugs market segmentation by product (SSRI, TSA, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). 

• The market share growth by the SSRI segment will be significant for the market growth during the forecast period. The market's expansion is fueled by the abundance of SSRIs like fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram. Due to the high demand for SSRIs, numerous generic versions have been approved by significant nations and organizations, including the United States, the European Union (EU), and Japan. SSRIs with controlled release and sustained release are being developed by some businesses. During the forecast period, the market for these new drugs is expected to grow quickly.

Obsessive-Compulsive Disorder Drugs Market - Market Dynamics:

Key DRIVERS:

• A key factor driving growth in the obsessive-compulsive disorder drugs market is the rising prevalence of OCD.
• OCD is a mental illness that lasts a long time and is chronic. Due to individuals' drastic lifestyle shifts, OCD is prevalent in high-income nations.
• For instance, people are more likely to be influenced by fictitious images, intrusive thoughts, and urges when they are exposed to movie technologies. In high-income nations, OCD is ranked as the fourth most common mental illness.
• Men, women, and children all suffer from OCD. In the early stages of childhood, adolescence, or adulthood, it is most obvious. Over the forecast period, the market is anticipated to be driven by the disorder's high prevalence.

Major Trends:

• The rising use of off-label therapies is obsessive-compulsive disorder drugs market trend that is expected to have a positive impact during the forecast period.
• Prescription pharmacological treatments for OCD include off-label treatments from a variety of drug classes as well as several approved treatments.
• Off-label treatments like vortioxetine, duloxetine, esketamine, aripiprazole, duloxetine, vortioxetine, and risperidone are available despite the fact that the OCD drug market is dominated by approved treatments.
• Off-label treatments include vortioxetine, duloxetine, esketamine, and aripiprazole. Due to relapse and refractory to first-line therapies, many OCD treatment guidelines recommend using off-label therapies as second-line treatments.
• The utilization of off-name treatments will probably increment in the OCD drugs market over the forecast period because of the absence of improvement of new treatments.

Key Challenges:

• The difficulties in diagnosing OCD will be a major challenge hampering the obsessive-compulsive disorder drugs market during the forecast period.
• OCD is moderately a typical problem, however viable treatment is accessible, nonetheless, it is frequently underdiagnosed and undertreated by doctors because of the absence of evidential side effects.
• The OCD side effects might shift from people due to the non-revelation mindset of the patients, underneath recorded are a few troubles for doctors to analyze the OCD.
• Absent signs: Due to an inferiority complex and a lack of awareness, patients frequently conceal their symptoms and do not seek assistance. Repeated questioning, difficulty making decisions or completing them, procrastination, and constantly seeking assurance are some of the symptoms.
• OCD has become a major challenge to identify because it is difficult to distinguish it from other psychiatric disorders because most of them share similar symptoms.

To get detailed insights about inclusions and exclusions, buy the report 

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform 

What are the key data covered in this Obsessive-Compulsive Disorder Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Obsessive-Compulsive Disorder Drugs Market between 2022 and 2026
• Precise estimation of the size of the Obsessive-Compulsive Disorder Drugs Market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Obsessive-Compulsive Disorder Drugs Market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Obsessive-Compulsive Disorder Drugs Market vendors

Related Reports:

The central nervous system disorders therapeutics market size is expected to increase by USD 24.35 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.44%. The report extensively covers central nervous system disorders therapeutics market segmentation by type (depression drugs, multiple sclerosis drugs, schizophrenia drugs, bipolar disorder therapeutics, epilepsy drugs, and others) and geography (Europe, North America, Asia, and ROW). The increasing prevalence of CNS disorders is notably driving the central nervous system disorders therapeutics market growth.

According to Technavio's analyst, the dementia and movement disorder treatment market size is expected to be valued at USD 7.14 billion by 2026 with a progressing CAGR of 6.95%. This report further entails dementia and movement disorder treatment market segmentations, including drug class (MAO inhibitors, acetylcholinesterase inhibitors, glutamate inhibitors, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The growing geriatric population is notably driving dementia and movement disorder treatment market growth.

Browse for Technavio's Health Care Market Reports           

Table of contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 SSRI - Market size and forecast 2021-2026
• Exhibit 28: Chart on SSRI - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on SSRI - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on SSRI - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on SSRI - Year-over-year growth 2021-2026 (%)

• 5.4 TSA - Market size and forecast 2021-2026
• Exhibit 32: Chart on TSA - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on TSA - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on TSA - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on TSA - Year-over-year growth 2021-2026 (%)

• 5.5 Others - Market size and forecast 2021-2026
• Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Product
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 France - Market size and forecast 2021-2026
• Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.11 Canada - Market size and forecast 2021-2026
• Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 88: Matrix on vendor position and classification

• 10.3 AbbVie Inc.
• Exhibit 89: AbbVie Inc. - Overview
• Exhibit 90: AbbVie Inc. - Product / Service
• Exhibit 91: AbbVie Inc. - Key offerings

• 10.4 Apotex Inc.
• Exhibit 92: Apotex Inc. - Overview
• Exhibit 93: Apotex Inc. - Product / Service
• Exhibit 94: Apotex Inc. - Key offerings

• 10.5 Biohaven Pharmaceutical Holding Co. Ltd.
• Exhibit 95: Biohaven Pharmaceutical Holding Co. Ltd. - Overview
• Exhibit 96: Biohaven Pharmaceutical Holding Co. Ltd. - Product / Service
• Exhibit 97: Biohaven Pharmaceutical Holding Co. Ltd. - Key offerings

• 10.6 Dr. Reddys Laboratories Ltd.
• Exhibit 98: Dr. Reddys Laboratories Ltd. - Overview
• Exhibit 99: Dr. Reddys Laboratories Ltd. - Business segments
• Exhibit 100: Dr. Reddys Laboratories Ltd. - Key offerings
• Exhibit 101: Dr. Reddys Laboratories Ltd. - Segment focus

• 10.7 Eli Lilly and Co.
• Exhibit 102: Eli Lilly and Co. - Overview
• Exhibit 103: Eli Lilly and Co. - Product / Service
• Exhibit 104: Eli Lilly and Co. - Key offerings

• 10.8 GlaxoSmithKline Plc
• Exhibit 105: GlaxoSmithKline Plc - Overview
• Exhibit 106: GlaxoSmithKline Plc - Business segments
• Exhibit 107: GlaxoSmithKline Plc - Key news
• Exhibit 108: GlaxoSmithKline Plc - Key offerings
• Exhibit 109: GlaxoSmithKline Plc - Segment focus

• 10.9 H Lundbeck AS
• Exhibit 110: H Lundbeck AS - Overview
• Exhibit 111: H Lundbeck AS - Product / Service
• Exhibit 112: H Lundbeck AS - Key offerings

• 10.10 Jazz Pharmaceuticals Plc
• Exhibit 113: Jazz Pharmaceuticals Plc - Overview
• Exhibit 114: Jazz Pharmaceuticals Plc - Product / Service
• Exhibit 115: Jazz Pharmaceuticals Plc - Key news
• Exhibit 116: Jazz Pharmaceuticals Plc - Key offerings

• 10.11 Novartis AG
• Exhibit 117: Novartis AG - Overview
• Exhibit 118: Novartis AG - Business segments
• Exhibit 119: Novartis AG - Key offerings
• Exhibit 120: Novartis AG - Segment focus

• 10.12 Pfizer Inc.
• Exhibit 121: Pfizer Inc. - Overview
• Exhibit 122: Pfizer Inc. - Product / Service
• Exhibit 123: Pfizer Inc. - Key news
• Exhibit 124: Pfizer Inc. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 125: Inclusions checklist
• Exhibit 126: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 127: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 128: Research methodology
• Exhibit 129: Validation techniques employed for market sizing
• Exhibit 130: Information sources

• 11.5 List of abbreviations
• Exhibit 131: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Infiniti Research, Inc.